CCL

Összesen 12 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM003614
Első szerző:Baráth Sándor (biológus)
Cím:The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients / Baráth Sándor, Soltész Pál, Kiss Emese, Aleksza Magdolna, Zeher Margit, Szegedi Gyula, Sipka Sándor
Dátum:2007
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity. - 40 : 7 (2007), p. 521-528. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Kiss Emese (1960-) (belgyógyász, immunológus) Aleksza Magdolna Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Sipka Sándor (1945-) (laboratóriumi szakorvos)
Internet cím:elektronikus változat
DOI
Borító:

2.

001-es BibID:BIBFORM038629
035-os BibID:PMID:9272279
Első szerző:Csípő István (vegyész)
Cím:Serum complement activation of SLE patients during plasmapheresis / Csipő I., Kávai M., Kiss E., Bedő Z., Csongor J., Szegedi Gy., Philbert F., Cohen J. H.
Dátum:1997
ISSN:0891-6934
Megjegyzések:The erythrocyte complement receptor 1 (ECR1)-immune complex binding assay is a sensitive method for the determination of complement fragments which can be activated by bovine serum albumin (BSA)-anti-BSA in vitro. When the C3b/C4b containing bovine serum albumin (BSA)-anti-BSA was formed in the presence of the serum of patients with systemic lupus erythematosus (SLE) its binding to ECR1 was found to be lower than that formed in sera of normal volunteers. The plasmapheresis of SLE patients homozygous for the CR1/E high density allele displays a beneficial effect on the formation of C3b/C4b containing BSA-anti-BSA and its binding to ECR1. There was no significant correlation between the serum C3/C4 level and the percentage of C3b/C4b containing BSA-anti-BSA binding to the ECR1 of SLE patients during plasmapheresis. At the same time, there was an inverse correlation between the serum immune complex level and the ECR1 binding, which was significant in 3 of 5 cases. These data suggest that, besides the determination of different components of complement activation, the functional assay of complement activation might be useful in monitoring the effect of plasmapheresis in SLE.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
0 (Antibodies)
0 (Antigen-Antibody Complex)
0 (Receptors, Complement 3b)
0 (Serum Albumin, Bovine)
80295-43-8 (Complement C3b)
80295-50-7 (Complement C4b)
Adult
Animals
Antibodies/immunology
Antigen-Antibody Complex/blood
Cattle
Complement Activation/immunology
Complement C3b/immunology
Complement C4b/immunology
Erythrocytes/immunology
Female
Humans
Lupus Erythematosus, Systemic/blood/immunology
Male
Middle Aged
Plasmapheresis
Receptors, Complement 3b/immunology
Serum Albumin, Bovine/immunology
Megjelenés:Autoimmunity. - 25 : 3 (1997), p. 139-146. -
További szerzők:Kávai Mária (1930-) (vegyész) Kiss Emese (1960-) (belgyógyász, immunológus) Bedő Zoltán Csongor József Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Philbert, F. Cohen, J. H. M.
Borító:

3.

001-es BibID:BIBFORM033501
035-os BibID:PMID:17453714 WOS:000246340100001
Első szerző:Csípő István (vegyész)
Cím:Determination of ligand binding capacity of soluble Fc gamma RII and Fc gamma RIII in sera of patients with SLE / Istvan Csipo, Sandor Barath, Emese Kiss, Gabriella Szucs, Gyula Szegedi, Maria Kavai
Dátum:2007
ISSN:0891-6934
Megjegyzések:BACKGROUND: Soluble, human low affinity Fcgamma receptors, such as sFcgammaRII and sFcgammaRIII, are known to play a pathologic role in different diseases. Sandwich ELISAs had previously been applied for the specific detection and determination of these soluble receptors. In these ELISAs, commercial monoclonal antibodies (Ab) were used as capture antibodies with monoclonal or polyclonal antibodies serving as detector Abs. Increased levels of cell-free FcgammaRIII have been detected in patients with lupus but the functions and levels of sFcgammaRII have not been fully characterized yet. OBJECTIVES: The aim of this work was to determine the ligand binding capacities and levels of soluble FcgammaRII and FcgammaRIII in sera of patients with systemic lupus erythematosus (SLE). Moreover, correlation between the levels of sFcgammaRII and sFcgammaRIII and the clinical activity of the disease were investigated. METHODS: Sera of 47 patients with SLE, and 51 healthy subjects were analyzed. In the newly developed indirect sandwich ELISAs commercial monoclonal anti-FcgammaRs are used as capture antibodies, and the ligand of FcgammaRII and FcgammaRIII, an artificial immune complex (IC), serves as a detection component replacing the second antibodies used in previous methods. RESULTS: The ligand binding capacity of both soluble FcgammaRII and sFcgammaRIII were elevated in the sera of SLE patients compared to control samples. This increase was significant in patients with the active disease (n = 30; p < 0.01). It was also revealed that a substantial part of the soluble Fcgamma receptors in these patients was bound in vivo to circulating IC. CONCLUSION: These newly developed ELISAs are probably more phisiologically relevant than other previous assays because they detect the circulating receptors on the basis their in vitro ligan binding capacities. Therefore this method can separately measure the levels of the soluble, free FcgammaRs and those bound circulating IC in vivo.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Autoimmunity 40 : 3 (2007), p. 165-168. -
További szerzők:Baráth Sándor (1977-) (biológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kávai Mária (1930-) (vegyész)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM038628
035-os BibID:PMID:9161700
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:CR1 density polymorphism and expression on erythrocytes of patients with systemic lupus erythematosus / Kiss E., Csipő I., Cohen J. H., Reveil B., Kávai M., Szegedi Gy.
Dátum:1996
ISSN:0891-6934
Megjegyzések:The present study investigated the expressed number of CR1 on erythrocytes (E) in relationship of the CR1 density genotype from 46 patients with systemic lupus erythematosus (SLE) and 47 healthy volunteers. The CR1 genotype was determined by a method based on polymerase chain reaction (PCR) amplification of the genomic DNA fragment of 1.8 kb separated by HindIII endonuclease digestion and agarose gel electrophoresis. Our data supported the earlier results that the number of binding sites/E for monoclonal anti-CR1 decreased among SLE patients compared with normal individuals having the same alleles for the CR1/E density. At the same time the novelty of our recent results was that the decreased expression of CR1 on E correlated significantly with kidney involvement in patients homozygous for the CR1/E high density allele (HH). These data suggest that the deficiency of the detectable number of CR1 on erythrocytes is acquired in this SLE population.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
0 (Receptors, Complement)
0 (Receptors, Complement 3b)
Erythrocytes/chemistry/immunology
Female
Genotype
Heterozygote
Homozygote
Humans
Lupus Erythematosus, Systemic/genetics/metabolism/pathology
Male
Polymorphism, Genetic/genetics
Polymorphism, Restriction Fragment Length
Receptors, Complement/genetics
Receptors, Complement 3b/biosynthesis/genetics/immunology
Severity of Illness Index
Megjelenés:Autoimmunity. - 25 : 1 (1996), p. 53-58. -
További szerzők:Cohen, J. H. M. Reveil, B. Kávai Mária (1930-) (vegyész) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Csípő István (1953-) (vegyész)
Borító:

5.

001-es BibID:BIBFORM020653
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients / Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G.
Dátum:2006
Megjegyzések:Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Objectives were to determine endothelial dysfunction with a non-invasive method in lupus patients and to analyse correlation with risk factors and atherosclerotic complications. Sixty-one SLE patients and 26 healthy age- and sex-matched control subjects were entered into the study. The diameters of brachial artery at rest, during reactive hyperaemia, and after glyceril trinitrate administration, as well as the intima-media thickness of the common carotid artery were measured using high-resolution B-mode ultrasonography. Demographic characteristics, lipid profile, paraoxonase activity, concentration of anti-phospholipid antibodies and anti-oxLDL were assessed together with atherosclerotic complications. The endothelium dependent vasodilation (FMD) was significantly impaired in SLE patients as compared to controls. The absolute difference of vessel diameter (Deltad) was 0.25+/-0.15 mm vs. 0.38+/-0.16 mm (p=0.001), and Deltad as in percent of the rest diameter was 7.31+/-5.2% vs. 9.86+/-3.87% (p=0.013) in lupus patients and controls, respectively. Nitrate mediated dilation (NMD) did not differ. FMD negatively correlated with age, systolic and diastolic blood pressure in SLE, but did not show significant correlation with the other examined parameters. However, FMD significantly differed between SLE patients with (5.54+/-4.36%) and without (8.81+/-5.28%) cardiovascular complications (p=0.01). The determination of flow-mediated vasodilation is a useful method to detect endothelial dysfunction in lupus patients, as reduced capacity of brachial artery may distinguish between SLE patients and healthy subjects, as well as lupus patients with and without atherosclerotic vascular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Autoimmunity. - 27 : 4 (2006), p. 211-217. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Kocsis Zsolt (1987-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

6.

001-es BibID:BIBFORM009776
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Anti-nuscleosome antibody, a reliable indicator for lupus nephritis / Kiss E., Lakos G., Szegedi G., Poor G., Szodoray P.
Dátum:2009
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity. - 42 : 5 (2009), p. 393-398. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Poór Gyula Szodoray Péter (1973-) (belgyógyász, orvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM033370
035-os BibID:WOS:000174053900007 PMID:11908707
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines / Pál Soltész, Magdolna Aleksza, Péter Antal-Szalmás, Gabriella Lakos, Gyula Szegedi, Emese Kiss
Dátum:2002
ISSN:0891-6934
Megjegyzések:To examine the possible effect of plasmapheresis on the ratio of Th1/Th2 type cytokine-secreting cells we recruited eight patients with active systemic lupus erythematosus into the present study. They all failed to respond to conventional therapy. A sensitive multiparametric flow cytometric analysis was used for the detection of intracellular IL-4, IL-10 and IFN-gamma. Stimulated peripheral blood cells were analysed by this procedure. Plasmapheresis was performed every second day for three occasions, using a continuous flow type blood cell separator, and a total of 100 ml/body weight kg plasma was removed. Patients received 1 mg/kg/day methylprednisolone during this period. As a result of the procedure, the rate of IFNgamma positive Th cells increased, while the rate of IL-4 and IL-10 expressing CD4 positive cells decreased. Together with these observations the concentration of anti-ds-DNA antibodies decreased after plasmapheresis. A decrease in disease activity index (SLE-DAI) indicated the clinical effectiveness of the therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Autoimmunity. - 35 : 1 (2002), p. 51-56. -
További szerzők:Aleksza Magdolna Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM013921
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Comparative assessment of vascular function in autoimmune rheumatic diseases : consideration of prevention and treatment / Soltész Pál, Kerekes György, Dér Henrietta, Szűcs Gabriella, Szántó Sándor, Kiss Emese, Bodolay Edit, Zeher Margit, Tímár Orsolya, Szodoray Péter, Szegedi Gyula, Szekanecz Zoltán
Dátum:2011
ISSN:1568-9972
Megjegyzések:Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis or other types of vasculopathy leading to increased cardio- and cerebrovascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. The characteristics of vasculopathies may significantly differ depending on the underlying disease. While classical accelerated atherosclerosis has been associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or spondyloarthropathies (SpA), obliterative vasculopathy may rather be characteristic for systemic sclerosis (SSc) or mixed connective tissue disease (MCTD). Antiphospholipid antibodies have been implicated in vasculopathies underlying SLE, antiphospholipid syndrome (APS), RA and MCTD. There is also heterogeneity with respect to inflammatory risk factors. Cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin 6 (IL-6) and immune complexes are primarily involved in arthritides, such as RA, SpA, as well as in SLE. On the other hand, autoantibodies including anti-oxLDL anti-cardiolipin and anti-beta2GPI are rather involved in SLE- and APS-associated vasculopathies. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have just been published, and similar recommendations in connective tissue diseases are to be developed soon.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - 10 : 7 (2011), p. 416-425. -
További szerzők:Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Dér Henrietta (1977-) (orvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Tímár Orsolya (1980-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
elektronikus változat
Borító:

9.

001-es BibID:BIBFORM007083
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Cardiac manifestations in antiphospholipid syndrome / Soltesz, P., Szekanecz, Z., Kiss, E., Shoenfeld, Y.
Dátum:2007
ISSN:1568-9972 (Print)
Megjegyzések:Antiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of Libman-Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart, control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize cardiovascular risk in these individuals.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antibodies
Antiphospholipid
Antiphospholipid Syndrome
Atherosclerosis
Autoantibodies
Cardiovascular Diseases
Humans
Risk Factors
Thrombosis
Megjelenés:Autoimmunity Reviews. - 6 : 6 (2007), p. 379-386. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Shoenfeld, Yehuda
Internet cím:elektronikus változat
elektronikus változat
DOI
Borító:

10.

001-es BibID:BIBFORM040289
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Malignancies and soluble tumor antigens in rheumatic diseases / Szekanecz E., András C., Sándor Z., Antal-Szalmás P., Szántó J., Tamási L., Kiss E., Szekanecz Z.
Dátum:2006
ISSN:1568-9972
Megjegyzések:Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 6 : 1 (2006), p. 42-47. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szántó János (1949-) (onkológus szakorvos) Tamási László Kiss Emese (1960-) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM006180
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus : associations with organ manifestations, immunolaboratory markers and disease activity indices / Éva Szekanecz, Gabriella Szűcs, Zoltán Szekanecz, Tünde Tarr, Péter Antal-Szalmás, Szilvia Szamosi, János Szántó, Emese Kiss
Dátum:2008
Megjegyzések:Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected increased production of CA15-3, CA19-9 and CA125 in rheumatoid arthritis (RA). The production of some TAAs may also be increased in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and other connective tissue diseases. Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. OBJECTIVES: We assessed levels of TAAs in the sera of SSc, SLE patients, patients with infectious diseases and healthy subjects. Serum TAA levels were correlated with each other, as well as with disease activity markers and organ involvement. METHODS: TAAs including CEA, CA15-3, CA72-4, CA125 and CA19-9 were assessed by immunoassay in the sera of 92 patients with SSc, 40 patients with SLE, 50 age- and sex-matched healthy controls, as well as with 40 patients with current bacterial or viral infections. Normal upper limits for these TAAs were 3.4 mg/l, 25 kU/l, 6.9 kU/l, 35 kU/l and 34 kU/l, respectively. RESULTS: There were significantly more SSc patients showing abnormally high levels of CA19-9 (8.8% vs 2.0%), CA125 (11.0% vs 6.0%) and CA15-3 (28.4% vs 14.0%) in comparison to controls (p < 0.05). In SLE, significantly more patients had elevated levels of CEA (32.5% vs 20.0%), CA19-9 (7.5% vs 2.0%), CA125 (15.0% vs 6.0%) and CA72-4 (15.0% vs 8.0%) than did controls (p < 0.05). The mean absolute serum levels of CEA (6.6+/-1.7 vs 1.8+/-1.4 mg/l) and CA15-3 (22.9 +/- 1.8 vs 18.6 +/- 2.2 kU/l) were also significantly higher in SSc compared to controls (p < 0.05). We found numerous correlations between the serum levels of different TAAs within the SSc and SLE population. Among SSc patients, serum CEA (R = 0.290; p = 0.005), CA15-3 (R = 0.260; p = 0.020) and CA19-9 (R = 0.257; p = 0.013) correlated with renal involvement. Serum CA15-3 also correlated with joint involvement (R = 0.329; p = 0.003), ANA positivity (R = 0.288; p = 0.010) and CRP levels (R = 0.407; p < 0.001). Within the SLE population, serum CA72-4 correlated with central nervous involvement (R = 0.624; p = 0.004) and CA125 correlated with the SLEDAI composite activity index (R = 0.666; p = 0.002). Patients with infections exerted serum TAA patterns similar to healthy controls. CONCLUSION: The concentration of some TAAs may be elevated in the sera of patients with SSc or SLE in comparison to healthy subjects. Pathogenically, most of these TAAs contain carbohydrate motifs and thus they may be involved in inflammation-associated adhesive events. Furthermore, the production of some TAAs may correlate with organ involvement or disease activity in scleroderma or lupus.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Autoimmunity. - 31 : 4 (2008), p. 372-376. -
További szerzők:Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

12.

001-es BibID:BIBFORM009772
Első szerző:Szodoray Péter (belgyógyász, orvos)
Cím:Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus / Szodoray P., Tarr T., Tumpek J., Kappelmayer J., Lakos G., Poor G., Szegedi G., Kiss E.
Dátum:2009
ISSN:0891-6934 (Print)
Megjegyzések:Lupus anticoagulant (LA) and b2-glikoprotein I (b2GPI) dependent anti-cardiolipin (aCL) are part of the diagnostic criteria both of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Anti-phospholipid antibodies (aPL) may also bind to other phospholipids and/or protein co-factors. In the present study, besides aCL and anti-b2GPI, antibodies directed against phosphatidylserine, prothrombin (PT) and annexin V (aANX) were measured in 85 randomly selected SLE patients, 14 suffering from secondary APS. LA was detected by hemostasis tests. Correlations were determined between rare aPLs and clinical manifestations, including thrombotic events. Anti-cardiolipin IgG was positive in 14 patients, aCL IgM in 8, anti-b2GPI IgG in 4 and IgM in 5 patients. LA was detected in nine cases. Seven patients were positive for antiphosphatidylserine (aPS) IgG, nine for aPS IgM, while anti-PT (aPT) IgG was positive in nine cases. aPT IgM and antiaANX were negative in all patients. Correlation was found between aPS and aCL antibodies. The frequency and concentration of rare anti-phospholipid/co-factor antibodies was higher in patients with secondary APS. The presence of such rare aPLs cumulated in APS patients, their presence increased the frequency of thrombotic events in the entire study population, furthermore in patients positive for LA or aCL. Rare anti-phospholipid/co-factor antibodies were found in 12% of an un-selected lupus patient population. Their presence was more frequent in patients with secondary APS, and further increased the risk of thrombotic complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity. - 42 : 6 (2009), p. 497-506. -
További szerzők:Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Tumpek Judit (1944-) (orvosi laboratóriumi szakorvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Poór Gyula Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.